Biosion has developed a proprietary, state-of-the-art platform called H³ Antibody Technology that enables discovery of multiple therapeutic candidates with superior properties.

The Platform enables identification of antibodies with efficient internalization rates, providing promising candidates for Antibody Drug Conjugates (ADCs).

The platform is a rapid and powerful engineering tool to create multifunctional therapeutic antibodies that can simultaneously bind to multiple distinct epitopes on a target or to multiple targets, re...